Innate Pharma Reports Phase 1 Data for IPH4502 and Sets 3.6 mg/kg Dose
Key Facts
Innate Pharma announced preliminary Phase 1 data on November 18, 2026, for IPH4502, an antibody-drug conjugate targeting Nectin-4 in patients with advanced solid tumors. The company said the maximum tolerated dose was 3.6 mg/kg, with stomatitis the only reported dose-limiting toxicity. It said no cases of febrile neutropenia or dose-limiting hematologic toxicity had been recorded. Chief Executive Jonathan Dickinson said the Phase 1 results "provide an encouraging basis for continuing the development of IPH4502." The drug remains in clinical development and has not received marketing authorization in the European Union or approval from the U.S. Food and Drug Administration.
The dose-escalation study included 76 patients across 6 dose levels from 0.6 to 3.6 mg/kg, with treatment administered once every three weeks. The median number of prior systemic treatment lines was 3.5, and participants had more than 10 tumor types. These figures describe a group of patients who had received multiple prior treatments in a study covering different types of advanced solid tumors. The company identified 3.6 mg/kg every three weeks as the maximum tolerated dose. Stomatitis was the reported dose-limiting toxicity, with no cases of febrile neutropenia or dose-limiting hematologic toxicity recorded.
In the non-urothelial tumor group at the maximum tolerated dose, the company reported an objective response rate of 33%, based on 2 responses among 6 patients. The result reflects observed activity in a small group at this dose level. In urothelial cancer, the study included 19 patients, all of whom had previously received enfortumab vedotin. The company recorded 3 partial responses at intermediate dose levels, one confirmed and two unconfirmed. The unconfirmed disease control rate in this group was 68.4%.
On safety, the company said that, as of the data cutoff on August 17, 2026, treatment-related adverse events of Grade 3 or higher had occurred in 43.4% of patients. This included Grade 3 or higher anemia in 11.8% of patients. These rates are based on the period ending at the data cutoff set by the company. The company stressed that IPH4502 remains in clinical development and that its safety and efficacy have not been established for commercial use. The drug has also not received marketing authorization in the European Union or approval from the U.S. Food and Drug Administration.
Innate Pharma plans to begin dose optimization in patients with urothelial cancer who have previously received enfortumab vedotin, targeting enrollment of the first patient in the first half of 2027. The study will evaluate two doses on days 1 and 8 of each three-week treatment cycle. Dickinson said the company would focus on optimizing the dose and schedule before defining a recommended Phase 2 regimen. This puts the urothelial cancer group, which included 19 patients, at the center of the drug's next development plan. The company did not announce another start date for this step in the data provided.
To fund development, the company said cash, cash equivalents and financial assets totaled 96.8 million euros on September 30, 2026. It said its cash runway was expected to extend through the end of the first quarter of 2028. In Paris trading on November 18, through the investor relations page update at 10:50, the company's shares fell 7.13% to 1.12 euros. EL7 data showed IPHA shares closed at 1.33 dollars on November 17. Reliable data on the stock's high or low during the November 17 session are not available here.